Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

about

Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Item

http://www.wikidata.org/entity/Q47625039

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Out-of-Pocket Cost Is a Barrie ...... in Inflammatory Bowel Disease.

@en

Out-of-Pocket Cost Is a Barrie ...... in Inflammatory Bowel Disease.

@nl

type

Item

label

Out-of-Pocket Cost Is a Barrie ...... in Inflammatory Bowel Disease.

@en

Out-of-Pocket Cost Is a Barrie ...... in Inflammatory Bowel Disease.

@nl

prefLabel

Out-of-Pocket Cost Is a Barrie ...... in Inflammatory Bowel Disease.

@en

Out-of-Pocket Cost Is a Barrie ...... in Inflammatory Bowel Disease.

@nl

P1476

Out-of-Pocket Cost Is a Barrie ...... in Inflammatory Bowel Disease.

@en

P2093

Erin Burton

http://www.w3.org/2001/XMLSchema#string

James P Campbell

http://www.w3.org/2001/XMLSchema#string

Michael Shaw

http://www.w3.org/2001/XMLSchema#string

Shelly Wymer

http://www.w3.org/2001/XMLSchema#string

P2860

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices.

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.

Tailoring treatment to the individual patient: drug monitoring.

Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.

Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.

Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.

Willingness to pay for complete symptom relief of gastroesophageal reflux disease.

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.

P2888

s10620-017-4808-3

P304

3336-3343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10620-017-4808-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Byron P Vaughn

P577

2017-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29052818

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases